Navigation Links
Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Date:8/19/2007

Estimates Peak Worldwide Transplant Opportunity of Over $400 Million

Annually

CAMBRIDGE, Mass., Aug. 2 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) today announced that its second phase 3 trial of Mozobil(TM) (plerixafor) has successfully met its primary and secondary endpoints, demonstrating positive results in multiple myeloma (MM) similar to those reported two weeks ago in non-Hodgkin's lymphoma.

The combined strength of these two trials -- in which patients with two types of cancer achieved more rapid and effective mobilization of stem cells in preparation for transplant than patients treated with current therapies -- will support Mozobil's regulatory approval, commercialization, and likely adoption as a standard of care in transplantation.

The randomized, double-blind, placebo-controlled trial included 302 patients who were undergoing a hematopoietic stem cell transplant (HSCT) for multiple myeloma at medical centers in the United States, Canada, and Europe. Like the previous trial, it examined the effectiveness of Mozobil in increasing the number of hematopoietic stem cells collected for a transplant, comparing the stem cell yield from patients treated with Mozobil following G- CSF to patients treated with placebo following G-CSF.

In the primary efficacy endpoint, 72 percent of patients treated with Mozobil and G-CSF achieved the target threshold for collection of at least 6 million CD34+cells/kg from the peripheral blood with two days or fewer of apheresis sessions, compared with 34 percent of patients in the G-CSF/placebo group. This two-fold increase was statistically significant in favor of the Mozobil-treated patients (p<0.0001). Like th
'/>"/>

SOURCE Genzyme Corp.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
8. Sygnis Pharma AG announces date for presentation of clinical results
9. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
11. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 29, 2014  United Therapeutics Corporation (NASDAQ: ... for the District of New Jersey ... case against Sandoz, Inc. regarding United Therapeutics, Remodulin ® ... ruled that U.S. Patent No. 6,765,117 is both valid ... marketing its generic product until the expiration of that ...
(Date:8/29/2014)... According to the new ... (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User (Research, ... Synthesis, NGS, DNA, RNAi) - Global Forecast to ... Market is expected to reach $1,712.1 Million by ... a CAGR of 9.8% from 2014 to 2019.. ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4District Court Decision Received In Remodulin Patent Case 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4
... Spherix Incorporated (NASDAQ: SPEX ) -- an ... and atherosclerosis, and providers of technical and regulatory consulting ... today announced that Dr. Claire Kruger, Chief Executive Officer, ... corporate overview at the Rodman & Renshaw 13th Annual ...
... ® Technologies, Inc., a world leader in personal and ... receive the coveted Orange Innovation Award in the 10th annual ... innovative approach to the design, development and manufacture of ... Sudden Cardiac Arrest . The Orange Innovation ...
Cached Medicine Technology:Spherix Incorporated to Present at the Rodman & Renshaw 13th Annual Healthcare Conference 2HeartSine® Technologies Named One of the Most Innovative Businesses in the United Kingdom 2
(Date:8/30/2014)... 2014 According to Bloomberg , ... requires Takeda Pharmaceutical Co. and Eli Lilly & Co. ... that the drugmakers concealed information about a risk of ... case, Allen v. Takeda Pharmaceuticals North America Inc. (12-cv-00064), ... of Louisiana (Lafayette).* , According to Bloomberg, Takeda and ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 ... a Spa-on-Wheels which offers the complete spa experience ... inviting lighting and the most important ingredient of ... "the dedicated licensed pro's! People will enjoy the ... continues Kaplan-Pelle. The website reads, "Step into the ...
(Date:8/30/2014)... Plains, NJ (PRWEB) August 30, 2014 ... first facilities in New Jersey and even in the ... technology that takes inches off of patients’ waists with ... freezing cells in small sections, Vanquish is more inclusive ... pain. Patients lay comfortably under panels about one ...
(Date:8/30/2014)... Jackson, Tenn. (PRWEB) August 30, 2014 ... people around the country for the past several ... the Tennessee Hyperbaric Center have announced a scholarship ... PTSD. This announcement follows a meeting held this ... , In recent years, reporters have shed light ...
(Date:8/30/2014)... Insomnia causes disturbances in every aspect of life. ... developed insomnia and the steps often used to return back ... to the show at this link: Dr. Carol Francis ... 30, and will be podcasted at this link (Click ... DrCarolFrancisTalkRadio.com. , "Insomnia causes countless unrecognized complications. Weight ...
Breaking Medicine News(10 mins):Health News:The Law Office of Melinda J. Helbock A.P.C. Comments on Decision to Uphold $9 Billion Actos Award 2Health News:Hands On Mobile Massage and Spa of Long Island Now Offers a Spa-on-wheels 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:Tennessee Hyperbaric Center Offering HBOT Scholarships to Veterans 2Health News:Sleepless Nights, Exhausting Days, Mental Fog – Relief for Insomnia With Clinical Psychologist Dr. Carol Francis 2
... and Mehmet Oz, MD, Launch Daily Syndicated ... Newspaper Column, ... E? Who better to keep the health momentum going than the YOU ... expert for The Oprah Winfrey Show. King Features Syndicate and,RealAge.com announce the ...
... Texas University of Texas Medical Branch at Galveston ... weapon against respiratory syncytial virus, the most common cause ... an effort to find an effective antiviral therapy for ... molecule to interfere with the genetic machinery that RSV ...
... Response Essentially Met but Donations Still Needed to Prepare,for ... WASHINGTON, May 5 The American Red Cross,today ... the Southeastern,Virginia tornadoes but donations to its Disaster Relief ... the next disaster, particularly with the,beginning of hurricane season ...
... Exclusive License for Pulse!! Virtual Learning Platform for ... Clinical Skills and Decision Making Training, ... developer of,game-based technology solutions for training, experimentation and,decision-making analysis, ... System for the exclusive, worldwide rights to Pulse!! the,Virtual ...
... Herley Industries, Inc.,(Nasdaq: HRLY ) announced today ... U.S. Government on all existing criminal and civil,claims. These ... had been scheduled for trial on May 5, 2008 ... control oscillators in January 2001 and,two contracts involving the ...
... a previously unrealized mechanism by which the epidermal growth ... cancer cells through a kinase-independent mechanism. The research, published ... journal Cancer Cell, provides a rationale for the less ... at interfering with kinase activity and suggests new directions ...
Cached Medicine News:Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 2Health News:Need a Daily Dose of Good Health Advice to Keep You Going? 3Health News:New agent strikes at respiratory syncytial virus replication 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 2Health News:Generous Donors Allow Red Cross to Respond Swiftly and Effectively to Southeastern Virginia Tornadoes 3Health News:Game-Based Technology to Meet Demand for Improved Medical Teaching and Training 2Health News:Game-Based Technology to Meet Demand for Improved Medical Teaching and Training 3Health News:Herley Announces Settlement Agreement with U.S. Government 2Health News:Herley Announces Settlement Agreement with U.S. Government 3Health News:EGFR protects cancer cells from starvation via a kinase-independent mechanism 2
... WideBiter Punch series facilitates fast and effective ... smooth, anatomically shaped meniscal rim. The flat, ... to access even the tightest joint spaces. ... Inc., 20 years of engineering experience in ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... series facilitates fast and effective resection of ... shaped meniscal rim. The flat, crescent-shaped tip ... even the tightest joint spaces. Made in ... years of engineering experience in arthroscopy hand ...
... facilitates fast and effective resection of meniscal ... meniscal rim. The flat, crescent-shaped tip has ... the tightest joint spaces. Made in the ... of engineering experience in arthroscopy hand instrument ...
Medicine Products: